Abstract
This in vitro study evaluated the activities of vancomycin, LY333328, and teicoplanin alone and in combination with gentamicin, rifampin, and RP59500 against Staphylococcus aureus isolates with intermediate susceptibilities to vancomycin. Ampicillin-sulbactam and trovafloxacin were also evaluated. LY333328 and ampicillin-sulbactam resulted in bactericidal activity against all isolates. The combination of gentamicin with glycopeptides showed synergistic activity, while rifampin had no added benefit.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Ampicillin / pharmacology
-
Anti-Bacterial Agents / pharmacology*
-
Antibiotics, Antitubercular / pharmacology
-
Drug Therapy, Combination / pharmacology*
-
Fluoroquinolones*
-
Gentamicins / pharmacology
-
Glycopeptides
-
Lipoglycopeptides
-
Microbial Sensitivity Tests
-
Naphthyridines / pharmacology
-
Rifampin / pharmacology
-
Staphylococcus aureus / drug effects*
-
Sulbactam / pharmacology
-
Teicoplanin / pharmacology
-
Time Factors
-
Vancomycin / pharmacology
-
Virginiamycin / pharmacology
Substances
-
Anti-Bacterial Agents
-
Antibiotics, Antitubercular
-
Fluoroquinolones
-
Gentamicins
-
Glycopeptides
-
Lipoglycopeptides
-
Naphthyridines
-
Virginiamycin
-
quinupristin-dalfopristin
-
Teicoplanin
-
sultamicillin
-
Vancomycin
-
Ampicillin
-
trovafloxacin
-
oritavancin
-
Sulbactam
-
Rifampin